230 related articles for article (PubMed ID: 30474436)
1. The molecular characterization and therapeutic strategies of papillary renal cell carcinoma.
Chen Q; Cheng L; Li Q
Expert Rev Anticancer Ther; 2019 Feb; 19(2):169-175. PubMed ID: 30474436
[No Abstract] [Full Text] [Related]
2. Integrated Phenotypic/Genotypic Analysis of Papillary Renal Cell Carcinoma Subtypes: Identification of Prognostic Markers, Cancer-related Pathways, and Implications for Therapy.
Saleeb RM; Plant P; Tawedrous E; Krizova A; Brimo F; Evans AJ; Wala SJ; Bartlett J; Ding Q; Boles D; Rotando F; Farag M; Yousef GM
Eur Urol Focus; 2018 Sep; 4(5):740-748. PubMed ID: 28753789
[TBL] [Abstract][Full Text] [Related]
3. Pathology, therapy and prognosis of papillary renal carcinoma.
Fernandes DS; Lopes JM
Future Oncol; 2015; 11(1):121-32. PubMed ID: 25572787
[TBL] [Abstract][Full Text] [Related]
4. Papillary renal cell carcinoma: A review of the current therapeutic landscape.
Courthod G; Tucci M; Di Maio M; Scagliotti GV
Crit Rev Oncol Hematol; 2015 Oct; 96(1):100-12. PubMed ID: 26052049
[TBL] [Abstract][Full Text] [Related]
5. Oncocytic papillary renal cell carcinoma: A clinicopathological and genetic analysis and indolent clinical course in 14 cases.
Han G; Yu W; Chu J; Liu Y; Jiang Y; Li Y; Zhang W
Pathol Res Pract; 2017 Jan; 213(1):1-6. PubMed ID: 27931799
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling.
Pal SK; Ali SM; Yakirevich E; Geynisman DM; Karam JA; Elvin JA; Frampton GM; Huang X; Lin DI; Rosenzweig M; Lipson D; Stephens PJ; Ross JS; Miller VA; Agarwal N; Shuch B; Choueiri TK; Chung JH
Eur Urol; 2018 Jan; 73(1):71-78. PubMed ID: 28592388
[TBL] [Abstract][Full Text] [Related]
7. Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population.
Lindor NM; Dechet CB; Greene MH; Jenkins RB; Zincke MT; Weaver AL; Wilson M; Zincke H; Liu W
Genet Test; 2001; 5(2):101-6. PubMed ID: 11551094
[TBL] [Abstract][Full Text] [Related]
8. MET alterations in biphasic squamoid alveolar papillary renal cell carcinomas and clinicopathological features.
Denize T; Just PA; Sibony M; Blons H; Timsit MO; Drossart T; Jakubowicz D; Broudin C; Morini A; Molina T; Vano Y; Auvray-Kuentz M; Richard S; Mejean A; Gimenez Roqueplo AP; Burnichon N; Verkarre V
Mod Pathol; 2021 Mar; 34(3):647-659. PubMed ID: 32770124
[TBL] [Abstract][Full Text] [Related]
9. Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines.
Yang Y; Ricketts CJ; Vocke CD; Killian JK; Padilla-Nash HM; Lang M; Wei D; Lee YH; Wangsa D; Sourbier C; Meltzer PS; Ried T; Merino MJ; Metwalli AR; Ball MW; Srinivasan R; Linehan WM
Genes Chromosomes Cancer; 2021 Jun; 60(6):434-446. PubMed ID: 33527590
[TBL] [Abstract][Full Text] [Related]
10. The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models.
Schuller AG; Barry ER; Jones RD; Henry RE; Frigault MM; Beran G; Linsenmayer D; Hattersley M; Smith A; Wilson J; Cairo S; Déas O; Nicolle D; Adam A; Zinda M; Reimer C; Fawell SE; Clark EA; D'Cruz CM
Clin Cancer Res; 2015 Jun; 21(12):2811-9. PubMed ID: 25779944
[TBL] [Abstract][Full Text] [Related]
11. Papillary renal cell carcinoma with cytologic and molecular genetic features overlapping with renal oncocytoma: Analysis of 10 cases.
Michalova K; Steiner P; Alaghehbandan R; Trpkov K; Martinek P; Grossmann P; Montiel DP; Sperga M; Straka L; Prochazkova K; Cempirkova D; Horava V; Bulimbasic S; Pivovarcikova K; Daum O; Ondic O; Rotterova P; Michal M; Hora M; Hes O
Ann Diagn Pathol; 2018 Aug; 35():1-6. PubMed ID: 30072012
[TBL] [Abstract][Full Text] [Related]
12. Three-gene risk model in papillary renal cell carcinoma: a robust likelihood-based survival analysis.
Wang Y; Yan K; Lin J; Wang J; Zheng Z; Li X; Hua Z; Bu Y; Shi J; Sun S; Li X; Liu Y; Bi J
Aging (Albany NY); 2020 Nov; 12(21):21854-21873. PubMed ID: 33154194
[TBL] [Abstract][Full Text] [Related]
13. Papillary Renal Cell Carcinoma (PRCC): An Update.
Akhtar M; Al-Bozom IA; Al Hussain T
Adv Anat Pathol; 2019 Mar; 26(2):124-132. PubMed ID: 30507616
[TBL] [Abstract][Full Text] [Related]
14. Warthin-like papillary renal cell carcinoma: Clinicopathologic, morphologic, immunohistochemical and molecular genetic analysis of 11 cases.
Skenderi F; Ulamec M; Vanecek T; Martinek P; Alaghehbandan R; Foix MP; Babankova I; Montiel DP; Alvarado-Cabrero I; Svajdler M; Dubinský P; Cempirkova D; Pavlovsky M; Vranic S; Daum O; Ondic O; Pivovarcikova K; Michalova K; Hora M; Rotterova P; Stehlikova A; Dusek M; Michal M; Hes O
Ann Diagn Pathol; 2017 Apr; 27():48-56. PubMed ID: 28325361
[TBL] [Abstract][Full Text] [Related]
15. Single-cell chromatin accessibility landscape in kidney identifies additional cell-of-origin in heterogenous papillary renal cell carcinoma.
Wang Q; Zhang Y; Zhang B; Fu Y; Zhao X; Zhang J; Zuo K; Xing Y; Jiang S; Qin Z; Li E; Guo H; Liu Z; Yang J
Nat Commun; 2022 Jan; 13(1):31. PubMed ID: 35013217
[TBL] [Abstract][Full Text] [Related]
16. MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array.
Albiges L; Guegan J; Le Formal A; Verkarre V; Rioux-Leclercq N; Sibony M; Bernhard JC; Camparo P; Merabet Z; Molinie V; Allory Y; Orear C; Couvé S; Gad S; Patard JJ; Escudier B
Clin Cancer Res; 2014 Jul; 20(13):3411-21. PubMed ID: 24658158
[TBL] [Abstract][Full Text] [Related]
17. Papillary renal cell carcinoma: current and controversial issues.
Angori S; Lobo J; Moch H
Curr Opin Urol; 2022 Jul; 32(4):344-351. PubMed ID: 35674688
[TBL] [Abstract][Full Text] [Related]
18. The underlying molecular mechanism and potential drugs for treatment in papillary renal cell carcinoma: A study based on TCGA and Cmap datasets.
Pang JS; Li ZK; Lin P; Wang XD; Chen G; Yan HB; Li SH
Oncol Rep; 2019 Apr; 41(4):2089-2102. PubMed ID: 30816528
[TBL] [Abstract][Full Text] [Related]
19. Recommendations for the Management of Rare Kidney Cancers.
Giles RH; Choueiri TK; Heng DY; Albiges L; Hsieh JJ; Linehan WM; Pal S; Maskens D; Paseman B; Jonasch E; Malouf G; Molina AM; Pickering L; Shuch B; Srinivas S; Srinivasan R; Tannir NM; Bex A
Eur Urol; 2017 Dec; 72(6):974-983. PubMed ID: 28720391
[TBL] [Abstract][Full Text] [Related]
20. [Papillary renal cell carcinoma: morphological subtypes, clinical and histopathological considerations].
Henry N; Rouach Y; Nguyen K; Verkarre V; Mejean A; Timsit MO
Prog Urol; 2010 Jun; 20(6):393-401. PubMed ID: 20538202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
